GLP1R and type 2 diabetes mellitus: Modulation of the incretin signalling system by either GLP-1 analogues directly or by stabilising the circulating GLP-1 by inhibition of dipeptidyl peptidase 4 (DPP4) is currently used as a treatment strategy for type 2 diabetes [17].